Zusammenfassung
Das gegenwärtige Staging- und TNM-System, das zuletzt 1997 revidiert wurde, wartet aufgrund sich verbessernder Behandlungsprognosen für einzelne Patientengruppen als auch einer immer besseren Kenntnis pathologisch-anatomischer Prognosefaktoren beim Bronchialkarzinom auf eine weitere Erneuerung. Insbesondere lymphogen fortgeschrittene Tumoren, T4- und M1-Situationen sind bis dato teilweise nicht differenziert genug erfasst, was für eine kleine, aber bedeutsame Patientengruppe an der Grenze zwischen kurativer und palliativer Therapie unzureichend erscheint. Maßgeblich für das individuelle Staging sollte ein zurückhaltender, abgestufter Ansatz sein, der stets die therapeutischen Konsequenzen im Auge hat. Innovative Stagingverfahren wie die Positronenemissionstomographie müssen angesichts überwiegend palliativer Therapieansätze auf eine breitere klinische Erfordernis hin als auch im Kosten-Nutzen-Vergleich noch differenzierter bewertet werden als bisher.
Abstract
The present staging and TNM system for lung cancer is under debate. After revision in 1997, the prognoses of subgroups of patients have improved due to advanced therapeutic concepts, and a deeper insight has been attained into prognostic factors based on pathological anatomy. Especially tumours with lymphogenic spread, T4 and M1 situations are described insufficiently, which could be meaningful for a small but important subgroup of patients who may or may not profit from a curative approach. The individual staging should be based on a sparing stepwise algorithm always keeping the therapeutic consequences in mind. Innovative staging procedures such as positron emission tomography require further evaluation on their use for the large group of palliatively treated patients, as well as cost-benefit aspects.
Literatur
Batevik R, Grong K, Segadal L, Stangeland L (2005) The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer 47:173–181
Berghmans T, Lafitte JJ, Thiriaux J et al. (2004) Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45:339–348
Egermann U, Jaeggi K, Habicht JM et al. (2002) Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? Eur Respir J 19:464–468
Furak J, Trojan I, Szoke T et al. (2005) Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 79:241–247
Gdeedo A, Van Schil P, Corthouts B et al. (1997) Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10:1547–1551
Gu CD, Osaki T, Oyama T et al. (2002) Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival. Ann Surg 235:133–139
Herth FJ (2004) Mediastinal staging—the role of endobronchial and endo-oesophageal sonographic guided needle aspiration. Lung Cancer 45 [Suppl 2]:S63–S67
Huber RM, Stratakis DF (2004) Molecular oncology—perspectives in lung cancer. Lung Cancer 45 [Suppl 2]:S209–S213
Kim JH, Kim YT, Lim HK et al. (2003) Management for chest wall implantation of non-small cell lung cancer after fine-needle aspiration biopsy. Eur J Cardiothorac Surg 23:828–832
Le Chevalier T, for the IALT Investigators (2003) Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:2
Mountain CF (1994) Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 73:2589–2598
Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111:1710–1717
Naruke T, Tsuchiya R, Kondo H, Asamura H (2001) Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71:1759–1764
Okada M, Tsubota N, Yoshimura M et al. (1999) Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 68:326–330
Osaki T, Sugio K, Hanagiri T et al. (2003) Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg 75:1745–1751
Passlick B, Kubuschock B, Sienel W et al. (2002) Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases—results of a preliminary study. Eur J Cardiothorac Surg 21:520–526
Porte H, Siat J, Guibert B et al. (2001) Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg 71:981–985
Thomas M, Gatzemeier U, Goerg R et al. (2000) Empfehlungen zur Diagnostik des Bronchialkarzinoms. Pneumologie 54:361–371
van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379
Vansteenkiste JF, Dooms CA (2004) The role of positron emission tomography with18F-2-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir Mon 30:245–264
Verschakelen JA, de Wewer W, Bogaert J, Stroobants S (2004) Imaging: staging of lung cancer. Eur Respir Mon 30:214–244
Walsh GL, O’Connor M, Willis KM et al. (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60:1563–1570
Yeow KM, Su IH, Pan KT et al. (2004) Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest 126:748–754
Yoshino I, Nakanishi R, Osaki T et al. (1997) Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. Ann Thorac Surg 64:809–813
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schönfeld, N. Wie viel Staging braucht der Mensch?. Pneumologe 2, 118–122 (2005). https://doi.org/10.1007/s10405-005-0031-6
Issue Date:
DOI: https://doi.org/10.1007/s10405-005-0031-6